Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
BIOD pharma play, could bounce up!
ENTL on my screen....KISS has always been one of my favs!!!!
Thanks Briboy, PPTI super thin ask!!!
Did you see L2 change bid support firming up on PPTI!
PPTI slow and steady...strong support!
PPTI now .0026 x .0027 she's going ino the 3' imo!!! Good Morning by the way!
I agree with you, all companies need to communicate with the public, not everyweek, but keeping the shareholders up to date with what the company is doing and where its going. AND stick with the business plan. Does'nt matter if they are NASD or pinkies(especially pinkies)!!!!!
PPTI up and running!
SANKA is a coffee brand, that peelers drink after a hard night at work!
RNWF off and running....just needs more participants!
Morning...what a struggle to get out of bed, i don't know how you do it after an all-nighter!
Looks like its going to be a RED day out there!
CCTR news just released:
(CCTR) China Crescent Record $51 Million Revenue Through 3rd Qtr. and YTD Update Webcast Featuring Projects With (NVAE) Savanna and (NUBL) NuMobile Available on Website
2010-11-30 09:20 ET - News Release
DALLAS, TX -- (MARKET WIRE) -- 11/30/10
China Crescent Enterprises, Inc. (OTCBB: CCTR) has released a Third Quarter Review Webcast highlighting the Company's third quarter and YTD results. China Crescent reported $50.9 million in revenue through the first 9 months of the year, compared to $30.3 million for the same period in 2009, a 67% increase. Additionally, the Company's net income for the first 9 months of 2010 was $3.3 million, up from $1.9 million for the same period last year. The Webcast also provides an update on projects the Company is currently engaged in with NuMobile, Inc. (OTCBB: NUBL) and Savanna East Africa, Inc. (PINKSHEETS: NVAE) (OTCQB: NVAE). NuMobile and China Crescent are working on a special purpose Wi-Fi communication device pilot, while Savanna and China Crescent have partnered on the recent sale of GPS enabled radios in Nairobi.
China Crescent, along with NuMobile and Savanna East Africa, is part of the NewMarket Technology, Inc. Greenfield Partnership Program. The Greenfield program was launched in 2009 to accelerate the introduction of new technologies into emerging markets around the world where technology buying is on the rise, while improving return on investment (ROI) potential. The Greenfield program assists in providing startup and development stage partner companies the collaboration opportunities and support necessary to win key contracts and grow their businesses. Companies are chosen to participate in the partnership program based on their technology and service offerings in conjunction with the emerging geographic markets in which they currently participate, such as China, Latin America and East Africa.
The Webcast titled "China Crescent Third Quarter Review & YTD Webcast" is available for on demand viewing on the Company's corporate website, www.chinacrescent.com or directly at http://tinyurl.com/CCTRQ3Webcast.
Sign Up to Receive Regular China Crescent Investor Updates
Easily busting through the 3's hear at the open, target?
UPCO: Nice to see MrBigz, VZ, Doodg and yourself involved. I've always appreciated their views and comments!
Will let you know on STEM cell companys, but GNSZ (Cancer related) should be a good pop this morning.
GenSpera Expands G-202 Phase I Clinical Program
2010-11-30 08:02 ET - News Release
GenSpera, Inc. (OTCBB:GNSZ) announced its intention to expand its Phase I safety trial to study G-202 in relapsed, refractory cancer patients to the Cancer Therapy and Research Center (CTRC) at The University of Texas Health Science Center at San Antonio in San Antonio, TX. The expansion is dependent upon a successful review of the clinical protocol by the Health Science Center Institutional Review Board (IRB). The company anticipates admitting the first patient at this site in the first quarter of 2011.
“We are delighted that CTRC will be joining us as an active and enthusiastic partner in the Phase I clinical trial of our lead compound, G-202. The center has a strong history of cancer drug development and has evaluated more than 20 drugs that have gone on to eventual approval by the FDA,” said Craig Dionne, Ph.D., Chairman and CEO of GenSpera. “Their entry into the study will allow more rapid patient recruitment during the Phase Ib portion, in which we plan to expand enrollment at the maximum tolerated dose to get an early signal of potential activity in multiple cancer types. We are also delighted to facilitate access to G-202 to cancer patients in Southwest Texas.”
“It will be an important milestone for the local biotech industry,” said Susan Mooberry, Ph.D., interim director of the CTRC’s Institute for Drug Development. “It highlights the GenSpera and CTRC partnership, and our commitment to the local community. And it’s great for our patients.”
The G-202 study, enrolling patients with cancers that have progressed after treatment with other therapies, has been underway since January, 2010, at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, in Baltimore, MD, and the University of Wisconsin Carbone Cancer Center, in Madison, WI. The primary endpoints of the open-label, dose-escalation study will be to determine the safety, tolerability and pharmacokinetics of the drug, although the design allows the collection of efficacy data as well.
PRB (Probe Mining) had an awesome day today. We can expect some good news soon is my guess. Have a good evening there fringe!
FROGS....how they doing?
49ers and Cardinals....both 3-7 if you have insommnia!
cyclone....UPCO, expecting a pop?
Probe has been and continues to be good to me. This trend will continue north and we should expect to see it well over the $3 dollar mark. Solid company with a low float. Alerted many people out there to this gem.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=53311773&txt2find=prb
Whats your thoughts?
Thanksgiving's been good, nice to see you back TUNA. You playing anything these days....besides 360XBox?
Good evening, can't stay long, internet problems....what's going on?
For what company would that be for?
Who's BILL?
That Korean situation is going to get worse (i hope that it doesn't)!!!!
SBRH on watch...
ACTC approaching high of day of .084 +75%
ACTC on a roll-- > Advanced Cell Technology Receives FDA Clearance For the First Clinical Trial Using Embryonic Stem Cells to Treat Macular Degeneration
2010-11-22 08:00 ET - News Release
FDA Lifts Clinical Hold; Company to Commence a Phase I/II Clinical Trial at Multiple Centers
MARLBOROUGH, Mass. -- (Business Wire)
Advanced Cell Technology, Inc. (“ACT”; OTCBB:ACTC) announced today that the US Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application to immediately initiate a Phase I/II multicenter clinical trial using retinal cells derived from human embryonic stem cells (hESCs) to treat patients with Stargardt’s Macular Dystrophy (SMD), one of the most common forms of juvenile macular degeneration in the world. The decision removes the clinical hold that the FDA had placed on the trial.
Stargardt’s Macular Dystrophy causes progressive vision loss, usually starting in children between 10 to 20 years of age. Eventually, blindness results from photoreceptor loss associated with degeneration in the pigmented layer of the retina, called the retinal pigment epithelium (RPE). . “There is currently no treatment for Stargardt’s disease,” said Dr. Robert Lanza, ACT’s Chief Scientific Officer. “Using stem cells, we can generate a virtually unlimited supply of healthy RPE cells, which are the first cells to die off in SMD and other forms of macular degeneration. We’ve tested these cells in animal models of eye disease. In rats, we’ve seen 100% improvement in visual performance over untreated animals without any adverse effects. Our studies showed that the cells were capable of extensive rescue of photoreceptors in animals that otherwise would have gone blind. Near-normal function was also achieved in a mouse model of Stargardt’s disease. We hope to see a similar benefit in patients with various forms of macular degeneration.”
The Phase I/II trial will be a prospective, open-label study that is designed to determine the safety and tolerability of the RPE cells following sub-retinal transplantation to patients with advanced SMD. A total of twelve patients will be enrolled in the study at multiple clinical sites. The sites which are currently under consideration are the Jules Stein Eye Institute at UCLA (headed by Dr. Steven Schwartz); the Casey Eye Institute in Portland, Oregon (headed by Dr. Peter Francis of the Oregon Health Sciences University); the University of Massachusetts Memorial Medical Center in Worcester, Massachusetts (headed by Dr. Shalesh Kaushal, Chair of the Department of Ophthalmology); the UMDNJ – New Jersey Medical School in Newark, New Jersey (headed by Dr. Marco Zarbin, Chair, Institute of Ophthalmology and Visual Science); additional sites may be considered.
Earlier this year the FDA also granted Orphan Drug designation for the company’s RPE cells. As a result, the company is eligible to receive a number of benefits, including tax credits, access to grant funding for clinical trials such as this one, accelerated FDA approval, and allowance for marketing exclusivity after drug approval for a period of as long as seven years.
Raymond Lund, Ph.D., a scientific collaborator with ACT, and considered one of the world’s foremost experts in retinal cell physiology and vision restoration, commented, “The study results of ACT’s RPE cells implanted in the various animal models of macular degeneration was phenomenal. If ACT observes even a fraction of that benefit in humans, it will be nothing short of a home run."
“Initiating our macular degeneration clinical trial represents a significant milestone in the progress of developing human embryonic stem cell-based therapies aimed at large worldwide markets," said William M. Caldwell IV, ACT’s Chairman and CEO. "I think generations will look back at this time as one of the most exciting in the history of medicine. With the initiation of this clinical trial, and that of Geron’s earlier this fall, the field of regenerative medicine is poised to take embryonic stem cell therapies from the realm of nebulous potential to that of tangible and real treatments that will make a significant difference in the lives of millions of people worldwide. This is truly a ‘game changer’ for the medical community.”
Among the most common causes of untreatable blindness in the world are degenerative diseases of the retina. As many as thirty million people in the United States and Europe suffer from macular degeneration, which represents a $25-30 billion worldwide market that has yet to be effectively addressed. Approximately 10% of people ages 66 to 74 will have symptoms of macular degeneration, the vast majority the “dry” form of AMD – which is currently untreatable. The prevalence increases to 30% in patients 75 to 85 years of age.
“These patient numbers are staggering in size,” stated Edmund Mickunas, ACT’s Vice President of Regulatory, “and when the impact on health and quality-of-life is considered in that context, macular degeneration represents one of the more significant unmet medical needs in our society. With the momentum of this Stargardt’s trial, and the unique experience we have gained as one of the few companies in the world having succeeded in taking an hESC program into the clinic, we are preparing to extend our lead with an IND in the use for treating age-related macular degeneration, as well as filing to begin clinical trials in Europe, in the very near future.”
Xmas Activation....Party at Chee-Chow Restaurant where BB hangs out lol!
BB's a high ROLLER, put your money in if your looking to double your bet!
Morning DFB!
DTRO .0016 about to fall!
MDFI back up, good for a few flips!
DYNV -- DYNAMIC VENTURES CORPORATION UPDATES BUSINESSS OUTLOOK TO INCLUDE EXPANSION INTO THE REO MARKET
2010-11-18 08:50 ET - News Release
SCOTTSDALE, AZ, Nov. 18 /PRNewswire-FirstCall/ - Dynamic Ventures Corp. (OTC BB: DYNV), today announces an update to the 2011 and 2012 Information and Outlook to include expansion into the REO market.
DYNV is seeking funds of a minimum $10 million for the REO market. This will help DYNV to purchase homes at discounts to current appraised values from institutions who wish to lower their levels of inventories of REO foreclosed on properties in 2011. If this target is met, DYNV intends to try and double this in 2012.
"These numbers could get much higher based on our ability to secure additional financing to support further acquisitions" stated Dave Brown, VP of Business development for DYNV. He continued "our strong base of in-house and affiliated trades and our long history of success in the real estate market gives us a solid leg up on our competition in this space. We have the ability to to attain quicker turn over and higher profitability because of our multi-tiered profit points in both the retrofit and transactional process. In addition, our recent relationship with Nova Home Loans will streamline our ability to qualify buyers for the properties under our control."
By way of recap, the companies "Green" BBSI SIPs panel business continues to be strong with 2011 revenues projected to be at $22.5million and 2012 projections now topping $41 million. The recently announced $5.4 million hotel project is expected to be the first of many as customers become more attracted to the faster, more cost effective and GREEN components to this subsidiary. "Again here, our layered profitability through our trades adds solidly to our shareholder value" stated Brown.
In addition, revenues from Native American projects continue to be strong with 2011 and 2012 predicted to be at $11 million and $23 million respectively.
"Despite the negative and difficult state of the US real estate markets, we feel that this is the perfect time for rapid growth within our organization." said Brown.
For divorce proceedings? LOL
Is that an early Xmas present?
CTNO anyone?
MDFI ask .0069's are up!!!